Abacavir sulfate

Research use only, not for human use.

A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.

A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.HIV Infection Approved(In Vitro):Abacavir (15 and 150 μM, 0-120 h) sulfate inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines.Abacavir (15 and 150 μM, 18 h) sulfate significantly reduces cell migration and inhibits cell invasion.Abacavir sulfate induces fat apoptosis.(In Vivo):Abacavir (0-7.5 μg/mL, 100 μL, intrascrotal administration; 100 and 200 mg/kg, p.o.; 4 h) sulfate dose-dependently promoted thrombus formation.Abacavir (50 mg/kg/d; i.p.; 14 days) sulfate with 0.1 mg/kg/d Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice.

Abacavir (15 and 150 μM, 0-120 h) sulfate inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines.Abacavir (15 and 150 μM, 18 h) sulfate significantly reduces cell migration and inhibits cell invasion.Abacavir sulfate induces fat apoptosis. Cell Proliferation Assay Cell Line:PC3, LNCaP and WI-38 Concentration:15 and 150 μMIncubation Time:0, 24, 48, 72 and 96 h Result:Showed a dose-dependent growth inhibition on PC3 and LNCaP.Cell Cycle Analysis Cell Line:PC3 and LNCaP Concentration:150 μM Incubation Time:0, 18, 24, 48, 72, 96 and 120 h Result:Caused a very high accumulation of cells in S phase in PC3 and LNCaP cells, and G2/M phase increment was observed in PC3 cells.Cell Migration Assay Cell Line:PC3 and LNCaP Concentration:15 and 150 μM Incubation Time:18 h Result:Significantly reduced cell migration.Cell Invasion Assay Cell Line:PC3 and LNCaP Concentration:15 and 150 μM Incubation Time:18 h Result:Significantly inhibited cell invision.

Abacavir (0-7.5 μg/mL, 100 μL, intrascrotal administration; 100 and 200 mg/kg, p.o.; 4 h) sulfate dose-dependently promoted thrombus formation.Abacavir (50 mg/kg/d; i.p.; 14 days) sulfate with 0.1 mg/kg/d Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice. Animal Model:Male mice (9-weeks old, 22-30 g) - wild-type (WT) C57BL/6 or homozygous knockout (P2rx7 KO, B6.129P2-P2rx7tm1Gab/J) Dosage:2.5, 5 and 7.5 μg/mL, 100 μL or 100 and 200 mg/kg Administration:Intrascrotal or oral administration for 4 h Result:Dose-dependently promoted thrombus formation.Animal Model:NSGTM mice, patient-derived xenograft (PDX) cells of non-WNT/non-SHH, Group 3 and of SHH/ TP53-mutated medulloblastoma Dosage:50 mg/kg/d with 0.1 mg/kg/d Decitabine Administration:Intraperitoneal injection, daily for 14 days Result:Inhibited tumor growth and enhanced mouse survival.

Abacavir sulfate | Abacavir sulfate salt

Microbiology/Virology

HIV

HIV-1reverse-transcriptase

Infection

HIV Infection

188062-50-2

286.3323

C14H18N6O

>98% (HPLC)

10 mM in H2O

C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO.C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO.OS(=O)(=O)O

2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)-, sulfate (2:1)

(-20℃)

With Ice Pack

≥ 2 years